MiReven

MiReven is an Australian biotechnology company focused on developing microRNA-based therapeutics for the treatment of cancer. The company's core technology centers on microRNA-7 (miR-7), a potent tumor suppressor that is frequently downregulated in aggressive cancers. MiReven's therapeutic approach involves restoring miR-7 levels to simultaneously inhibit multiple oncogenic pathways, including those involving EGFR and Raf-1. Spun out of the Harry Perkins Institute of Medical Research, the company primarily targets refractory indications such as mesothelioma and hepatocellular carcinoma. MiReven is supported by the Medical Research Commercialisation Fund (MRCF) and aims to overcome drug resistance in solid tumors through its RNA-based replacement strategy.